An experimental gene therapy may be effective for MND patients with a newly discovered genetic mutation 01-Dec-2020 By Jane Byrne A neuroprotective drug which is already in development may be particularly effective for MND patients carrying a newly discovered genetic risk factor, helping to halt progression or even prevent the onset of the devastating degenerative disease.
Amgen joins neuroscience exodus 31-Oct-2019 By Ben Hargreaves In third quarter financials, Amgen announces that it will end its R&D efforts in neuroscience to focus on diseases with a ‘large public health impact.
